Cargando…
Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics
Type 2 diabetes mellitus (T2DM or T2D) is a devastating metabolic abnormality featured by insulin resistance, hyperglycemia, and hyperlipidemia. T2D provokes unique metabolic changes and compromises cardiovascular geometry and function. Meanwhile, T2D increases the overall risk for heart failure (HF...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465638/ https://www.ncbi.nlm.nih.gov/pubmed/35511596 http://dx.doi.org/10.1093/jmcb/mjac028 |
_version_ | 1784787843398238208 |
---|---|
author | Abudureyimu, Miyesaier Luo, Xuanming Wang, Xiang Sowers, James R Wang, Wenshuo Ge, Junbo Ren, Jun Zhang, Yingmei |
author_facet | Abudureyimu, Miyesaier Luo, Xuanming Wang, Xiang Sowers, James R Wang, Wenshuo Ge, Junbo Ren, Jun Zhang, Yingmei |
author_sort | Abudureyimu, Miyesaier |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM or T2D) is a devastating metabolic abnormality featured by insulin resistance, hyperglycemia, and hyperlipidemia. T2D provokes unique metabolic changes and compromises cardiovascular geometry and function. Meanwhile, T2D increases the overall risk for heart failure (HF) and acts independent of classical risk factors including coronary artery disease, hypertension, and valvular heart diseases. The incidence of HF is extremely high in patients with T2D and is manifested as HF with preserved, reduced, and midrange ejection fraction (HFpEF, HFrEF, and HFmrEF, respectively), all of which significantly worsen the prognosis for T2D. HFpEF is seen in approximately half of the HF cases and is defined as a heterogenous syndrome with discrete phenotypes, particularly in close association with metabolic syndrome. Nonetheless, management of HFpEF in T2D remains unclear, largely due to the poorly defined pathophysiology behind HFpEF. Here, in this review, we will summarize findings from multiple preclinical and clinical studies as well as recent clinical trials, mainly focusing on the pathophysiology, potential mechanisms, and therapies of HFpEF in T2D. |
format | Online Article Text |
id | pubmed-9465638 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-94656382022-09-13 Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics Abudureyimu, Miyesaier Luo, Xuanming Wang, Xiang Sowers, James R Wang, Wenshuo Ge, Junbo Ren, Jun Zhang, Yingmei J Mol Cell Biol Review Type 2 diabetes mellitus (T2DM or T2D) is a devastating metabolic abnormality featured by insulin resistance, hyperglycemia, and hyperlipidemia. T2D provokes unique metabolic changes and compromises cardiovascular geometry and function. Meanwhile, T2D increases the overall risk for heart failure (HF) and acts independent of classical risk factors including coronary artery disease, hypertension, and valvular heart diseases. The incidence of HF is extremely high in patients with T2D and is manifested as HF with preserved, reduced, and midrange ejection fraction (HFpEF, HFrEF, and HFmrEF, respectively), all of which significantly worsen the prognosis for T2D. HFpEF is seen in approximately half of the HF cases and is defined as a heterogenous syndrome with discrete phenotypes, particularly in close association with metabolic syndrome. Nonetheless, management of HFpEF in T2D remains unclear, largely due to the poorly defined pathophysiology behind HFpEF. Here, in this review, we will summarize findings from multiple preclinical and clinical studies as well as recent clinical trials, mainly focusing on the pathophysiology, potential mechanisms, and therapies of HFpEF in T2D. Oxford University Press 2022-05-03 /pmc/articles/PMC9465638/ /pubmed/35511596 http://dx.doi.org/10.1093/jmcb/mjac028 Text en © The Author(s) (2022). Published by Oxford University Press on behalf of Journal of Molecular Cell Biology, CEMCS, CAS. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Abudureyimu, Miyesaier Luo, Xuanming Wang, Xiang Sowers, James R Wang, Wenshuo Ge, Junbo Ren, Jun Zhang, Yingmei Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics |
title | Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics |
title_full | Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics |
title_fullStr | Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics |
title_full_unstemmed | Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics |
title_short | Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics |
title_sort | heart failure with preserved ejection fraction (hfpef) in type 2 diabetes mellitus: from pathophysiology to therapeutics |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465638/ https://www.ncbi.nlm.nih.gov/pubmed/35511596 http://dx.doi.org/10.1093/jmcb/mjac028 |
work_keys_str_mv | AT abudureyimumiyesaier heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics AT luoxuanming heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics AT wangxiang heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics AT sowersjamesr heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics AT wangwenshuo heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics AT gejunbo heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics AT renjun heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics AT zhangyingmei heartfailurewithpreservedejectionfractionhfpefintype2diabetesmellitusfrompathophysiologytotherapeutics |